Siren L.L.C. Sells 2,508,269 Shares of Tango Therapeutics, Inc. $TNGX

Siren L.L.C. decreased its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 30.7% in the 1st quarter, Holdings Channel reports. The firm owned 5,657,105 shares of the company’s stock after selling 2,508,269 shares during the period. Tango Therapeutics accounts for about 3.3% of Siren L.L.C.’s investment portfolio, making the stock its 6th biggest holding. Siren L.L.C.’s holdings in Tango Therapeutics were worth $118,347,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. State of Wyoming acquired a new position in Tango Therapeutics in the first quarter valued at $128,000. Dimensional Fund Advisors LP raised its holdings in shares of Tango Therapeutics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock valued at $10,237,000 after buying an additional 2,272 shares during the last quarter. Bleakley Financial Group LLC acquired a new stake in shares of Tango Therapeutics during the first quarter worth about $259,000. Candriam S.C.A. boosted its stake in shares of Tango Therapeutics by 79.1% during the first quarter. Candriam S.C.A. now owns 1,269,246 shares of the company’s stock worth $26,553,000 after buying an additional 560,434 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Tango Therapeutics by 10.2% during the first quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock worth $507,000 after buying an additional 2,251 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Stock Down 2.3%

Shares of Tango Therapeutics stock opened at $27.45 on Friday. The firm has a market cap of $3.97 billion, a price-to-earnings ratio of -33.07 and a beta of 1.12. Tango Therapeutics, Inc. has a 52-week low of $5.77 and a 52-week high of $34.39. The company’s 50-day simple moving average is $26.96 and its 200-day simple moving average is $20.57.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, meeting analysts’ consensus estimates of ($0.32). Equities research analysts anticipate that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Insider Buying and Selling

In other news, insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the transaction, the insider owned 115,743 shares in the company, valued at $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 81,000 shares of company stock valued at $1,989,630 over the last three months. 6.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Canaccord Genuity Group boosted their price target on Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Weiss Ratings cut Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Citigroup reiterated a “buy” rating on shares of Tango Therapeutics in a research note on Monday, April 27th. Wedbush upped their price target on Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Finally, UBS Group set a $55.00 price target on Tango Therapeutics in a report on Thursday, May 14th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tango Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $42.15.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.